Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) EBITDA: 2021-2024

Historic EBITDA for Biofrontera (BFRI) over the last 4 years, with Dec 2024 value amounting to -$17.2 million.

  • Biofrontera's EBITDA fell 26.57% to -$6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year increase of 9.02%. This contributed to the annual value of -$17.2 million for FY2024, which is 24.11% up from last year.
  • Per Biofrontera's latest filing, its EBITDA stood at -$17.2 million for FY2024, which was up 24.11% from -$22.7 million recorded in FY2023.
  • Biofrontera's EBITDA's 5-year high stood at -$17.2 million during FY2024, with a 5-year trough of -$25.2 million in FY2021.
  • Its 3-year average for EBITDA is -$19.5 million, with a median of -$18.6 million in 2022.
  • As far as peak fluctuations go, Biofrontera's EBITDA climbed by 26.27% in 2022, and later declined by 22.04% in 2023.
  • Biofrontera's EBITDA (Yearly) stood at -$25.2 million in 2021, then increased by 26.27% to -$18.6 million in 2022, then fell by 22.04% to -$22.7 million in 2023, then grew by 24.11% to -$17.2 million in 2024.